Overview

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Antilymphocyte Serum
Busulfan
Clofarabine
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Melphalan
Rituximab
Thiotepa
Thymoglobulin